International Stem Cell(ISCO)

Focus: International Stem Cell is a publicly traded biotechnology company focused on proprietary stem cell induction technology and cell therapy applications, operating at modest commercial scale with $9M in FY 2025 revenue.

Cell Therapy

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About International Stem Cell

AI assessmentNot Hiring

No open roles listed right now. Follow International Stem Cell to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$9M

Pipeline & Clinical Trials

High frequency pure tone audiometry

Hearing Loss, Sensorineural

N/A

Clinical Trials (1)

NCT04270916Prevalence and Impact on QoL From Ototoxicity in Cancer Survivors

N/A

Help build intelligence for International Stem Cell

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to emerging stem cell induction technology, a differentiated platform with potential to address multiple therapeutic areas including ophthalmology and neurology.
Public company status provides equity liquidity and formal governance, reducing startup operational uncertainty.
Early-stage pipeline with Phase 3 program (cultivated conjunctival transplantation for pterygium) offers opportunity to influence clinical development.

Watch Out For

Severe cash constraints: $1M cash position (FY 2025) with $9M revenue insufficient to fund operations; company is burning $200K+ annually and has zero active job openings, signaling hiring freeze or potential distress.
Unfocused pipeline: six programs across disparate indications (diabetes surgery, hearing loss, ophthalmology, stroke) suggest scattered strategic focus rather than coherent development strategy.
Minimal R&D investment ($657K in FY 2025, only 7% of revenue) inconsistent with biotech claims; limited scientific output (zero publications) raises questions about innovation capability.

Generated by Claude from International Stem Cell's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

High frequency audiometry

Quality of Life

N/A

Clinical Trials (1)

NCT04281953Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors

N/A

Bariatric Surgery

Type2 Diabetes

N/A

Clinical Trials (1)

NCT05092399Effects of VLCD and Bariatric Surgery in Patients With Type 2 Diabetes

N/A